Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

about

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS

P2860

Q58789448-DD616E7E-1441-4F08-9570-D208FAD977A9

P2860

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Item

http://www.wikidata.org/entity/Q38650602

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Alemtuzumab: a review of effic ...... remitting multiple sclerosis.

@en

type

Item

label

Alemtuzumab: a review of effic ...... remitting multiple sclerosis.

@en

prefLabel

Alemtuzumab: a review of effic ...... remitting multiple sclerosis.

@en

P1476

Alemtuzumab: a review of effic ...... remitting multiple sclerosis.

@en

P2093

Cristina Guarnera

http://www.w3.org/2001/XMLSchema#string

P2860

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

Alemtuzumab for Multiple Sclerosis.

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Alemtuzumab treatment of multiple sclerosis.

P304

871-879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S134398

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emanuela Mazzon

Placido Bramanti

P577

2017-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28761351

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

5522829

http://www.w3.org/2001/XMLSchema#string

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

about

P2860

P2860

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932